Onco Actu du 15 juin 2015

	1. Biologie
Boob tubes: Breast grown in lab will test cancer treatments [New Scientist] Mammary glands have been created using cells donated after breast reduction operations.
Study links gene to aggressive form of brain cancer [The Institute of Cancer Research] The new research is the largest ever genetic study of oligodendrogliomas, and provides important insights into their causes – and how they might be treated.
	3.1 Tabac
CDC, Sandman, and finding an "honest" appraisal of e-cigarettes [HealthNewsReview] A summary judgment of the “honesty” of the CDC release is a tough call because the evidence that exists doesn’t line up neatly with the fundamental questions we all have. The survey results give us snapshots of what kids are doing. But are the trends good or bad? That’s where too much of the arguing is rooted in beliefs and clouded by uncertainties.
	4.12 Biopsies liquides
Q&A With Elaine R. Mardis, PhD, on Integrating Clinical Genomics and Cancer Therapy [CANCER RESEARCH Catalyst] If we can successfully incorporate liquid biopsy to consistently monitor patients who have received such combination therapies, we would have a beautiful synthesis of all these different fields coming together to translate genomics into the next level of cancer care.
	4.7 Dép., diag. & prono. - Col de l'utérus
Cervical cancer 'not just a young woman's disease' [BBC News] The NHS cervical screening programme in England, Wales and Northern Ireland stops sending invitations for cervical screening after a woman reaches 65, although they can request to be screened after that time.
Older women 'ignoring cervical cancer danger' [The Guardian] “This review suggests that older women not getting themselves screened to prevent cervical cancer has become a significant contributor to the number contracting the disease."
	4.9 Dép., diag. & prono. - Sein
Breast-Cancer Screening [Now@NEJM] Some 20 cohort and 20 case-control studies, all conducted in the developed world (Australia, Canada, Europe, or the United States) were considered by the IARC working group to be informative for evaluating the effectiveness of mammographic screening programs, according to invitation or actual attendance, mostly at 2-year intervals.
	5.2 Pharma
Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study [The BMJ] Press releases are incomplete substitutes for the detailed information contained in complete response letters.
FDA: Drug Companies Routinely Hide The Reasons Their Drugs Are Rejected From Investors [Forbes] Seven times between August 11, 2008, and June 27, 2013, the Food and Drug Administration declined to approve a new medicine, in part, because patients were more likely to die when taking the drug than in a control group. Yet only one of those companies told investors – and the public – about that concern.
	5.3 Traitements - FDA, EMA,...
How Often Are Drugs Withdrawn For Safety or Effectiveness Reasons (and How Many)? Not Too Often in Recent Years, But There is a Tranche of Withdrawals Historically [FDA Law Blog] Of the 215 notices we were able to find, only 11 of them – or 5.1% – included a determination that a drug was withdrawn from sale for safety or effectiveness reasons.
	5.9.3 EHA
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial [ARIAD] The study now shows that with a median follow-up of approximately 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of approximately 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options.
Agios' top cancer drug notches more remissions on the way to Phase III [FierceBiotech] Now Agios has its eye on Phase III, working with partner Celgene to design a late-stage trial and begin enrollment in the second half of this year. The biotech has yet to disclose just which patient populations it'll target.
Results from Analyses of Revlimid® MCL-002 (SPRINT) Study Presented at EHA [Celgene] In the study, 254 patients were randomized 2:1 to receive either REVLIMID (n=170) or single agent cytarabine, rituximab, gemcitabine, fludarabine or chlorambucil (n=84).
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML [Novartis] ENEST1st data confirm the favorable benefit/risk profile of Tasigna in newly-diagnosed CML patients seen in the pivotal ENESTnd study.
Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control [Novartis] Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year.
Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma [Novartis] Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD.
Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia [AbbVie] Of the 49 patients evaluated, the overall response rate (ORR) was 84 percent (n=41/49), with 20 (41%) patients achieving a complete response (six patients achieved complete response with incomplete bone marrow recovery (CRi)), and 21 (43%) patients achieving a partial response (PR), one nodular.
Updated Results from MM-020/IFM 07-01 (First) Study of REVLIMID® Presented at European Hematology Annual Congress [Celgene] "The updated results of the FIRST study reinforce the survival advantage for continuous REVLIMID therapy in patients newly diagnosed with multiple myeloma," said Prof. Thierry Facon, MD, University of Lille and primary investigator of the study.
Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia [Novartis] Arzerra (ofatumumab) significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working.
Agios leukemia drug demonstrates impressive response rate: study [Reuters] Forty percent response "is remarkably exciting in this kind of patient population," said Dr. Eytan Stein, from Memorial Sloan Kettering Cancer Center in New York, who presented the data at the European Hematology Association.
	6. Lutte contre les cancers
Athletes Colin Jackson and Donovan Bailey urge prostate cancer 'fear factor' [BBC News] Between them, Jackson and Bailey won gold medals at Olympic Games and World Championships and broke world records, but now they have a new ambition - to highlight the risk of prostate cancer, particularly among black men.
	6.6 Publications
Nature retraction, resignation result after lung cancer cell lines “cannot be those specified" [Retraction Watch] We noted earlier this week that cell line substitution is a pretty typical cause of problems. But this seems to be a more serious strain of the common mistake.
Cancer paper pulled due to "identical text" from one published 6 days prior; author objects [Retraction Watch] Amy Heimberger at MD Anderson Cancer Center, the corresponding author on both papers, insists that the retraction was not warranted. She claims that the duplication simply represented “a baseline immunological phenotypic and functional characterization of the glioma cancer stem cells” required for each study.
	6.7.2 Applis
The innovators: the app that allows patients to track their illnesses [The Guardian] With prostate cancer, how often the toilet is used is tracked, for example. The app can also be used by people who have been released from hospital following major surgery.